High-risk Large B-cell Lymphoma (LBCL) research hub

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

This study compares a new treatment, axicabtagene ciloleucel, with standard care for adults recently diagnosed with high-risk large B-cell lymphoma. It aims to see if the new treatment works better as a first treatment option.